

1 **A peptidomic approach for the identification of antioxidant and ACE-**
2 **inhibitory peptides in sardinelle protein hydrolysates fermented by *Bacillus***
3 ***subtilis* A26 and *Bacillus amyloliquefaciens* An6**
4

5 **Ines Jemil^{1*}, Leticia Mora², Rim Nasri¹, Ola Abdelhedi¹, Maria-Concepción Aristoy²,**
6 **Mohamed Hajji¹, Moncef Nasri¹, Fidel Toldrá²**
7
8
9
10
11

12 ¹ *Laboratoire de Génie Enzymatique et de Microbiologie, Université de Sfax, Ecole Nationale*
13 *d'Ingénieurs de Sfax, B.P 1173-3038 Sfax, Tunisie*

14 ² *Instituto de Agroquímica y Tecnología de Alimentos (CSIC), Avenue Agustín Escardino 7,*
15 *Paterna, 46980 Valencia, Spain*
16
17
18
19
20
21
22
23
24
25
26

27 * Corresponding author. Tel.: +216 74 274 408; Fax: +216 74 275 595.

28 E-mail address: inesjemil1987@gmail.com

29 **ABSTRACT**

30 Antioxidant and angiotensin I-converting enzyme (ACE)-inhibitory activities of
31 sardinelle (*Sardinella aurita*) protein hydrolysates (SPHs) obtained by fermentation with
32 *Bacillus subtilis* A26 (SPH-A26) and *Bacillus amyloliquefaciens* An6 (SPH-An6) were
33 investigated. Both hydrolysates showed dose-dependent antioxidant activities evaluated using
34 various *in vitro* antioxidant assays. Further, they were found to exhibit ACE-inhibitory
35 activity. Peptides from SPH-A26 and SPH-An6 were analyzed by nESI-LC-MS/MS and
36 approximately 800 peptides were identified. Identified peptides derived mainly from myosin
37 (43% and 31% in SPH-An6 and SPH-A26, respectively). Several peptides identified in both
38 hydrolysates were found to share sequences with previously identified antioxidant and ACE-
39 inhibitory peptides based on Biopep database. Some of these peptides were selected for
40 synthesis and their biological activities were evaluated. Among the synthesized peptides,
41 NVPVYEGY and ITALAPSTM were found to be the most effective ACE-inhibitors with
42 IC₅₀ values of 0.21 and 0.23 mM, respectively. On the other hand, NVPVYEGY, which
43 exhibited the highest ACE-inhibitory activity, showed the highest reducing power and peroxy
44 radical scavenging activities, followed by SLEAQAKEY and GTEDELDKY. The results of
45 this study suggest that fermented sardinelle protein hydrolysates are a good source of natural
46 antioxidant peptides and could have the potential to act as hypotensive nutraceutical
47 ingredients.

48

49

50 **Keywords** : *Sardinella aurita*; Fermentation; Protein hydrolysates; Antioxidant activity;
51 ACE-inhibitory activity; Peptidomic analysis.

52

53

54 **1. Introduction**

55 Elevated blood pressure is one of the major independent risk factors for cardiovascular
56 disease (Harris, Cook, Kannel, Schatzkin, & Goldman, 1985). Angiotensin I-converting
57 enzyme (ACE, peptidyl dipeptide hydrolase) plays an important role in the renin-angiotensin
58 system, which regulates human blood pressure and fluid homeostasis. ACE converts the
59 inactive form of decapeptide angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) into a
60 powerful vasoconstrictor, the octapeptide angiotensin II by removing the C-terminal dipeptide
61 His-Leu (Lavoie & Sigmund, 2003). In addition, ACE inactivates the vasodilator bradykinin
62 (Lavoie & Sigmund, 2003). Therefore, the inhibition of ACE is considered to be a useful
63 approach in the treatment of hypertension.

64 Specific inhibitors of ACE, such as captopril, lisinopril and enalapril, have been shown to
65 be useful as antihypertensive drugs (Salveti, 1990). However, these ACE-inhibitory drugs
66 have some undesirable side effects such as cough, lost of taste, renal impairment and
67 angioneurotic edema (Cooper et al., 2006). Thus, the search for natural safe and more
68 effective ACE-inhibitory agents as alternative to synthetic drugs is necessary for the
69 prevention and treatment of hypertension.

70 As a result, the interest in identifying foods as potential natural sources of ACE-
71 inhibitory peptides has increased (Houston, 2005). In fact, several ACE-inhibitory peptides
72 have been isolated from various food sources such as Spanish dry-cured ham (Escudero et al.,
73 2013), soya milk (Tomatsu, Shimakage, Shinbo, Yamada, & Takahashi, 2013), goby muscle
74 protein (Nasri et al., 2013), jellyfish (Liu et al., 2013), smooth hound viscera (Abdelhedi et
75 al., 2016) and thornback ray muscle (Lassoued et al., 2015).

76 Organisms are constantly exposed to various forms of reactive oxygen species that lead to
77 the oxidation of proteins, nucleic acids and lipids. In addition, deterioration of many foods
78 occur due to the oxidation of lipids and formation of secondary lipid peroxidation products.

79 Therefore, a great interest has been developed to identify new antioxidant compounds from
80 different sources to overcome problems related to lipid peroxidation. Different recent studies
81 reported that peptides derived from certain protein hydrolysates, and especially from marine
82 sources, could act as potential antioxidants (Lassoued et al., 2015, Kleekayai et al., 2015,
83 Sudhakar, & Abdul Nazeer, 2015).

84 According to literature, the most widely used method for the production of protein
85 hydrolysates is the controlled enzymatic digestion. Few studies have been conducted on the
86 generation of biologically active peptides using microbial fermentation. In a previous work,
87 we reported the production of antioxidant and antibacterial protein hydrolysates from fish
88 meat fermented by *Bacillus subtilis* A26 (Jemil et al., 2014) and *Bacillus amyloliquefaciens*
89 An6 and their potential use *in vivo* for the treatment of hyperlipidemia in high-fat fed wistar
90 rats (Jemil et al., 2016). Fakhfakh, Ktari, Siala, & Nasri (2013) reported the production of
91 protein hydrolysates with high antioxidant potential from wool-waste by fermentation with a
92 new keratinolytic bacterium, *Bacillus pumilus* A1. In another study, Torino et al. (2013)
93 reported that solid-state fermented lentils by *Bacillus subtilis* showed ACE-inhibitory activity.
94 More recently, Chakka, Elias, Jini, Sakhare, & Bhaskar (2015) reported the production of
95 chicken liver protein hydrolysates by fermentation using the lactic acid bacteria *Pediococcus*
96 *acidilactici* NCIM5368.

97 Therefore, the aim of this study was to investigate the antioxidant and ACE-inhibitory
98 activities of fermented sardinelle protein hydrolysates and to identify potent bioactive peptide
99 sequences by LC-MS/MS. A peptidomic analysis based on Biopep database was done to
100 identify potential biopeptides that were synthesized and tested *in vitro*.

101

102 **2. Materials and methods**

103 **2.1. Reagents**

104 1,1-diphenyl-2-picrylhydrazyl (DPPH) and butylated hydroxyanisole (BHA) were
105 purchased from Sigma Chemical Co. (St. Louis, MO, USA). ACE from rabbit lung and ACE
106 synthetic substrate o-aminobenzoylglycyl-p-nitro-L-phenylalanyl-L-proline (Abz-Gly-Phe-
107 (NO₂)-Pro) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Acetonitrile,
108 methanol, and ethanol HPLC grade were from Scharlau (Scharlab SL, Barcelona, Spain). All
109 solutions were freshly prepared in bi-distilled water obtained from a Culligan system; the
110 resistivity was approximately 18 MΩ*cm.

111

112 **2.2.Material**

113 Sardinelle (*Sardinella aurita*) was freshly purchased from the local fish market of Sfax
114 City, Tunisia. The sample was packed in polyethylene bags, placed in ice with a sample/ice
115 ratio of approximately 1:3 (w/w) and transported to the laboratory within 30 min. Muscles
116 were separated and rinsed with cold distilled water to remove salts and other contaminants.

117

118 **2.3.Preparation of undigested sardinelle proteins (USP)**

119 Raw muscle from sardinelle (500 g) was cooked for 20 min at 100 °C in 1000 mL bi-
120 distilled water. The bones were removed from cooked fish and fillets were collected and dried
121 at 80 °C for 18 h. The dried fish preparation was minced to obtain USP.

122

123 **2.4. Production of fermented sardinelle protein hydrolysates**

124 *B. subtilis* A26 (CTM 50700) (Agrebi et al., 2009) and *B. amyloliquefaciens* An6 (Agrebi
125 et al., 2010), known to produce several proteolytic enzymes, were employed to obtain protein
126 hydrolysates through fermentation of sardinelle proteins. Inoculums were grown in medium
127 containing only powdered sardinelle meat (30 g/l; pH 8.0) as a unique carbon and nitrogen
128 source (Jemil et al., 2014). Media were autoclaved at 121 °C for 20 min. Cultivations were

129 conducted in 1000 mL Erlenmeyer flasks, containing 100 mL of culture medium. Incubations
 130 were carried out in a shaking incubator (Technico Ltd, Chennai, India) at 200 rpm for 24 h at
 131 37 °C. The growth of the microorganisms was estimated by the determination of colony
 132 forming units per milliliter. Cultures were then centrifuged at 8500×g for 30 min at 4 °C.
 133 Resulted cell-free supernatants containing SPHs were freeze dried (Bioblock Scientific Christ
 134 ALPHA 1-2, IllKrich-Cedex, France) and stored at - 20 °C. The freeze dried powders, with a
 135 yield of 0.3 and 0.35 g of dried powder g⁻¹ of USP, respectively, were evaluated for antioxidant
 136 and anti-ACE activities. All experiments were carried out in triplicate.

137

138 2.5. Determination of the degree of hydrolysis (DH)

139 DH was measured using o-phthaldialdehyde (OPA) following the method referred by
 140 Nielsen, Petersen, & Dambmann (2001). An aliquot of the sample (400 µl), at a concentration
 141 of 1 mg mL⁻¹, was added to 3 mL of OPA solution and homogenized for 5 seconds. The
 142 absorbance of mixtures was measured after 2 min at 340 nm. The same volume of distilled
 143 water instead of SPH sample was used as control. A serine standard was also prepared (0.1
 144 mg mL⁻¹).

145 The DH was expressed in percentage and calculated using the following formulas :

$$146 \quad DH = \frac{h}{h_{tot}} \times 100$$

147

$$148 \quad h = \frac{\text{Serine-NH}_2 - \beta}{\alpha}$$

149

$$150 \quad \text{Serine -NH}_2 = \frac{\text{Abs}_{\text{sample}} - \text{Abs}_{\text{control}}}{\text{Abs}_{\text{serine}} - \text{Abs}_{\text{control}}} \times \frac{0.9516 \times 0.1 \times 10}{W \times P}$$

151

152 where Abs_{sample} is the absorbance of SPH, Abs_{serine} is the absorbance of serine standard,
 153 Abs_{control} is the absorbance of control, W is the weight in grams of SPH sample in 100 mL and
 154 P is the protein content (%) of SPH. Constants values of the number of equivalent peptide
 155

156 bonds per gram of protein (h_{tot}), α and β were assumed to be 8.6 meq g^{-1} , 1 and 0.4,
157 respectively, since these are the recommended values for fish by Nielsen, Petersen, &
158 Dambmann (2001). Each experiment was done in triplicate.

159

160 **2.6. Chemical analysis**

161 Moisture and ash contents were determined according to the AOAC standard methods
162 930.15 and 942.05, respectively (AOAC. 2000). Total nitrogen content of SPHs and
163 undigested protein substrates were determined using the Kjeldahl method according to the
164 AOAC method number 984.13 (AOAC. 2000) and the equipment of BÜCHI Digestion Unit
165 K-424, Switzerland. Protein content was estimated by multiplying total nitrogen content by
166 the factor of 6.25. Fat content was determined gravimetrically after Soxhlet extraction of dried
167 samples with hexane for 2 h using heating mantle. All measurements were performed in
168 triplicate.

169

170 **2.7. Determination of ACE-inhibitory activity**

171 The ACE-inhibitory activity of SPHs and synthesized peptides was measured according
172 to Sentandreu & Toldrá (2006), based on the hydrolysis of the fluorescent substrate o-
173 aminobenzoylglycyl-p-nitro-L-phenylalanyl-L-proline (Abz-Gly-Phe-(NO₂)-Pro). A sample
174 solution (50 μL) was mixed with 50 μL of 150 mM Tris-base buffer (pH 8.3) containing 3 μM
175 mL^{-1} of ACE, and incubated for 10 min at 37 °C. Then, 200 μL of 150 mM Tris-HCl buffer
176 (pH 8.3) containing 1.125 M NaCl and 10 mM Abz-Gly-Phe-(NO₂)-Pro are added and
177 incubated at 37 °C for 45 min. The released o-aminobenzoylglycine (Abz-Gly) was measured
178 at 355 and 405 nm as excitation and emission wavelengths, respectively. ACE inhibition of
179 SPHs and the most active synthesized peptides was expressed as a percentage and the IC_{50} as

180 the amount of peptide required to inhibit 50% of ACE activity. Captopril was used as
181 positive control. The test was carried out in triplicate.

182

183 **2.8. Antioxidant activities**

184 **2.8.1. DPPH radical-scavenging assay**

185 The DPPH radical-scavenging activity of the hydrolysates was determined as described
186 by Bersuder, Hole, & Smith (1998), with minor changes. A 96 well microplate reader (Opsys
187 MR™, Dynex Technologies, VA, USA) with detection at 490 nm was used to carry out the
188 assay. A volume of 100 µL of each sample was added to 100 µL of 99.5% ethanol and 25 µL
189 of 0.02% DPPH in 99.5%. After 60 min in the dark, the absorption was measured at 490 nm.
190 The control was conducted in the same manner, except that distilled water was used instead of
191 sample.

192 The DPPH radical-scavenging activity was calculated as follows:

$$193 \text{ DPPH radical-scavenging activity (\%)} = \frac{A_{\text{control}} - A_{\text{sample}}}{A_{\text{control}}} \times 100$$

194

195 where A_{sample} is the absorbance of the solution containing the sample and A_{control} is the
196 absorbance of the control reaction. BHA was used as positive control. The test was carried out
197 in triplicate and the results were mean values.

198

199 **2.8.2. Reducing power assay**

200 The ability of SPHs and synthesized peptides to reduce Fe^{3+} was determined according
201 to the method of Yildirim, Mavi, & Kara (2001). The sample (1 mL) was mixed with 2.5 mL
202 of 0.2 M phosphate buffer (pH 6.6) and 2.5 mL of 1% (w/v) potassium ferricyanide solution
203 and incubated for 30 min at 50 °C. Thereafter, 2.5 mL of 10% (w/v) trichloroacetic acid was
204 added and the reaction mixture was then centrifuged for 10 min at 10,000×g. The supernatant

205 solution (2.5 mL) was mixed with 2.5 mL of distilled water and 0.5 mL of 1% (w/v) ferric
206 chloride and the absorbance was measured at 690 nm after 10 min of reaction time.
207 Alternatively, the assay can be miniaturized and carried out in 96-well plate, where volumes
208 of reagents were proportionally reduced. The absorbance of each well was read using a
209 microplate reader (Opsys MR™ 96-well microplate reader, Dynex Technologies, VA, USA).
210 Increases in absorbance values indicate higher reducing power capacity (Suryakanth et al.,
211 2012). BHA was used as positive control. The test was carried out in triplicate.

212

213 **2.8.3. β -carotene bleaching assay**

214 The ability of SPHs and synthesized peptides to prevent β -carotene bleaching was
215 assessed as described by Koleva, Van Beek, Linssen, De Groot, & Evstatieva (2002). A stock
216 solution of β -carotene/linoleic acid mixture was prepared by dissolving 0.5 mg of β -carotene,
217 20 μ L of linoleic acid and 200 μ L of Tween 80 in 1 mL of chloroform. The chloroform was
218 completely evaporated under vacuum in a rotatory evaporator at 40 °C, then 100 mL of
219 double-distilled water were added, and the resulting mixture was vigorously stirred. The
220 obtained emulsion obtained was freshly prepared before each experiment. Aliquots (2.5 mL)
221 of the β -carotene/linoleic acid emulsion were transferred to test tubes containing 0.5 mL of
222 SPHs samples. After one hour incubation at 50 °C, the absorbance of each sample was
223 measured at 470 nm. Regarding synthesized peptides, the assay was miniaturized and carried
224 out in 96-well plate, where all volumes were proportionally reduced. The absorbance of each
225 well was read using a 96 well microplate reader (Opsys MR™ 96-well microplate reader,
226 Dynex Technologies, VA, USA) with detection at 450 nm. A total of 200 μ L of the β -
227 carotene/linoleic acid mixture were added to each well containing 50 μ L of each synthesized
228 peptide. After one hour of incubation at 50 °C, the absorbance of each sample was measured
229 at 470 nm. BHA was used as positive control. The test was carried out in triplicate.

230 **2.8.4. Determination of metal chelating activity (ferrozine assay)**

231 The chelating activity of the SPHs for Fe²⁺ was measured according to the method
232 described by Dinis, Maderia, & Almeida (1994). Thus, a total of 150 µL of distilled water and
233 25 µL of FeCl₂ (2 mM) were added to 50 µL of hydrolysate, followed by the addition of 100
234 µL of ferrozine (5 mM) after 5 min. After a-10 min incubation at room temperature, the
235 absorbance of the Fe²⁺-ferrozine complex with red or violet color was measured at 562 nm.
236 The chelating activity of the antioxidant for Fe²⁺ was calculated according to the following
237 formula:

$$238 \text{ Ferrous ion-chelating activity (\%)} = \frac{(A_{\text{control}} + A_{\text{blank}} - A_{\text{sample}})}{A_{\text{control}}} \times 100$$

239 where A_{control} is the absorbance of the control (without sample), A_{blank} is the absorbance of the
240 blank (without ferrozine) and A_{sample} is the absorbance of SPHs. EDTA was used as positive
241 control. All determinations were performed in triplicate.

242

243 **2.8.5. Oxygen radical absorbance capacity (ORAC) assay**

244 ORAC of hydrolysates and synthesized peptides was carried out according to the
245 procedure reported by Dávalos, Gómez-Cordovés, Bartolomé, & (2004) with minor
246 modifications. The ORAC assay was measured using a Fluoroskan Ascent FL
247 (Thermo Electron Corporation, Waltham, MA). Briefly, the microplate equipped with an
248 incubator and wavelength-adjustable fluorescence filters was used to monitor for the reaction.
249 The temperature of the incubator was set at 37 °C, and fluorescence filters with excitation
250 wavelength of 485 nm and emission wavelength of 538 nm were used. AAPH was used as
251 peroxy generator and Trolox was used as antioxidant standard. The plate reader was
252 programmed to record the fluorescence of fluorescein on every cycle. Kinetic reading was
253 recorded for 100 cycles with 60 s per cycle setting. Trolox standards were prepared with
254 phosphate buffered saline (PBS) (75 mM, pH 7.4), which was used as blank. The samples

255 were diluted with PBS (75 mM, pH 7.4) to the proper concentration range for fitting the
256 linearity range of the standard curve. After loading 140 μ L of sample, standard and blank, and
257 70 μ L of the fluorescein solution (200 nM) into appointed wells according to the layout, the
258 microplate was incubated for 15 min in the plate reader, then 70 μ L of peroxy generator
259 AAPH (80 mM) was added to initiate the oxidation reaction. The final ORAC values were
260 calculated using a linear equation between the Trolox standards or sample concentration and
261 net area under the fluorescence decay curve. The ORAC value was expressed as micromolar
262 of Trolox equivalent (μ M TE) using the calibration curve of Trolox. All determinations were
263 performed in triplicate.

264

265 **2.9. Identification of peptides using nESI-LC–MS/MS**

266 Peptide identification was done using a nano-liquid chromatography system (Eksigent
267 of AB Sciex, CA) coupled to a quadrupole-time-of-flight (Q-ToF) system (TripleTOF®
268 5600+, AB Sciex Instruments, Framingham, MA) equipped with a nano-electrospray
269 ionization source (nano-ESI). Systems parameters were adjusted as previously published in
270 Mora, Escudero, Aristoy, & Toldrá (2015).

271 Regarding the spectra analysis, peak list generation and database search for the
272 identification of the peptides were done using Mascot Distiller v2.4.2.0 software (Matrix
273 Science, Inc., Boston, MA). NCBI nr protein database was used to identify the peptides with a
274 significance threshold $p < 0.05$ and a FDR (False Discovery Rate) of 1.5%. The tolerance on
275 the mass measurement was 100 ppm in MS mode and 0.3 Da in MS/MS ions. BIOPEP
276 (<http://www.uwm.edu.pl/biochemia/index.php/pl/biopep>) databases were used to search of
277 similar sequences previously described as ACE-inhibitory or antioxidant.

278

279 **2.10. Peptide synthesis**

280 The most promising sequences of identified peptides were synthesized by GenScript
281 Corporation (Piscataway, NJ, USA) in order to assess their *in vitro* activities. The synthesized
282 peptides and their purity were certified by analytical LC–MS.

283

284 **2.11. Statistical analyses**

285 Statistical analyses were performed with Stratgraphics ver. 5.1, professional edition
286 (Manugistics Corp., USA) using ANOVA analysis. Differences were considered significant at
287 $p < 0.05$.

288

289 **3. Results and discussion**

290 **3.1. Preparation and characterization of fermented sardinelle protein hydrolysates**

291 In this study, the fermentation of sardinelle muscle proteins was carried out during 24 h.
292 The extent of protein hydrolysis during fermentation by *B. subtilis* (A26) and *B.*
293 *amyloliquefaciens* (An6) strains was measured by assessing the degree of hydrolysis and the
294 proteolytic activity. The findings revealed that An6 strain showed a higher hydrolytic activity
295 (DH = 24.3%) in comparison with SPH-A26 that was 21.56%. The proteolytic activity in
296 cultures of A26 and An6, using sardinelle proteins as substrate, were estimated at 400 U mL^{-1}
297 and 250 U mL^{-1} , respectively. The high DH values obtained were mainly due to the
298 production of several proteases by the two strains. The difference in DH values could be
299 mainly due to the difference in the specificity of enzymes produced by the proteolytic bacteria
300 used and may reflect the generation of small sized bioactive peptides in the hydrolysate
301 mixtures. It has been reported that high DH values are suitable for the generation of
302 antioxidant and ACE-inhibitory peptides (Nasri et al., 2014).

303 The chemical composition of freeze dried SPHs was determined and compared to that
304 of undigested sardinelle proteins. The proximate composition of dried SMF showed that it had

305 high protein content (76.43% of dry matter basis). In fermented SPHs, protein content was
306 about 75%. The lipid level in the hydrolysates was about 0.7%, which is lower than that of
307 USP (15.65%). SPH-A26 and SPH-An6 had high ash content, 9.8% and 9%, respectively.

308

309 **3.2.ACE-inhibitory activity of SPHs**

310 The ACE-inhibitory activity of SPH-A26 and SPH-An6 was investigated at different
311 concentrations. As reported in Fig. 1, both fermented hydrolysates exhibited high ACE-
312 inhibitory activity in a dose dependent manner reaching $75.7\% \pm 0.66$ and $79.5\% \pm 0.33$ at 0.6
313 mg mL^{-1} for SPH-A26 and SPH-An6, respectively. The concentration of hydrolysates
314 required to inhibit 50% of the ACE activity (IC_{50} values) was determined and SPH-An6
315 showed an IC_{50} value of $0.21 \pm 0.001 \text{ mg mL}^{-1}$, whereas SPH-A26 showed an IC_{50} value of
316 $0.26 \pm 0.006 \text{ mg mL}^{-1}$. It is interesting to note that SPH-An6, which showed the highest DH
317 (DH= 24.3%), exhibited the lowest IC_{50} value. The IC_{50} values of the two hydrolysates were
318 lower than those of salmon skin collagen hydrolysate ($1.165 \pm 0.087 \text{ mg mL}^{-1}$) obtained by
319 treatment with alcalase and papain (Gu, Li, Liu, Yi, & Cai, 2011) and goby muscle
320 hydrolysates prepared with different proteases ($1.36\text{--}3.33 \text{ mg mL}^{-1}$) (Nasri et al., 2013). In
321 another study, Alemán et al. (2011) reported IC_{50} values between 0.34 and 1.6 mg mL^{-1} for
322 squid gelatine hydrolysates prepared by several commercial proteases. However, both IC_{50}
323 values were nearly similar to that of liquid state lentils fermented by *Lactobacillus plantarum*
324 ($\text{IC}_{50}= 0.20 \text{ mg mL}^{-1}$) (Torino et al., 2013).

325 No ACE-inhibitory activity was detected with USP. Therefore, the results indicated that
326 ACE-inhibitory peptides are encrypted within the sardinelle proteins and could be released
327 through the action of proteolytic enzymes derived from proteolytic bacteria during
328 fermentation.

329

330 **3.3. Antioxidant activities**

331 **3.3.1. DPPH free radical-scavenging activity**

332 DPPH is a stable free radical that shows maximum absorbance at 517 nm. When DPPH
333 radicals encounter a hydrogen-donating substrate such as an antioxidant, the radicals would be
334 scavenged and the absorbance is reduced (Shimada, Fujikawa, Yahara, & Nakamura, 1992).
335 The decrease in absorbance is taken as a measure for radical-scavenging activity. Fig. 2a
336 shows the DPPH radical-scavenging activity of SPHs and BHA, used as positive control, at
337 different concentrations. The results clearly indicated that both hydrolysates were able to
338 scavenge DPPH radical with a dose-dependent manner and SPH-An6 exhibited the highest
339 radical-scavenging activity ($70 \pm 0.8\%$ at 5 mg mL^{-1}). The obtained results are in line with
340 previous works reported by Morales-Medina, Tamm, Guadix, Guadix, & Drusch (2016) and
341 Bkhairia et al. (2016) who reported that the DPPH scavenging activity increases with
342 increasing protein hydrolysate concentrations. However, the two hydrolysates showed lower
343 radical scavenging activity than BHA (2 mM ; $92.5 \pm 1.7\%$). The obtained results suggested
344 that some peptides within sardinelle protein hydrolysates would be significantly strong radical
345 scavengers.

346

347 **3.3.2. Reducing power**

348 In this assay, the ability of hydrolysates to reduce Fe^{3+} to Fe^{2+} was determined. The
349 presence of antioxidants in the protein hydrolysate results in reduction of the Fe^{3+} /ferric
350 cyanide complex to the ferrous form. As shown in Fig. 2b, the reducing power activity (as
351 indicated by the absorbance at 690 nm) of both hydrolysates and BHA increased with
352 increasing concentrations. A little difference in the reducing power activities was observed
353 between the two hydrolysates. Nevertheless, both hydrolysates showed lower reducing power
354 than did BHA at the same concentrations.

3.3.3. Antioxidant activity measured by the β -carotene bleaching method

The antioxidant assay using the discoloration of β -carotene is widely employed to measure the antioxidant activity of bioactive compounds, because β -carotene is extremely susceptible to free radical-mediated oxidation of linoleic acid (Kumazawa et al., 2002). In this test, β -carotene undergoes a rapid discoloration in the absence of antioxidant, which results in the reduction in absorbance of the test solution with increasing reaction time. The presence of antioxidant hinders the extent of bleaching by neutralizing the linoleic hydroperoxyl radicals formed. The antioxidant activities of SPHs measured by β -carotene bleaching are reported in Fig. 2c. The two hydrolysates inhibited the oxidation of β -carotene at different degrees and in a dose-dependent manner. SPH-An6 showed slightly higher ability to prevent bleaching of β -carotene than did SPH-A26. However, the inhibition of β -carotene bleaching of both hydrolysates was lower than that obtained by BHA (92%). These results demonstrated that SPHs prevent β -carotene bleaching by potentially donating hydrogen atoms to peroxy radicals of linoleic acid.

369

3.3.4. Ferrous ion-chelating activity

The chelation of Fe^{2+} was used to determine the ability of protein hydrolysates in metal-chelating activity. Ferrozine quantitatively forms complex with Fe^{2+} ions. In the presence of chelating agents, the complex formation is disrupted, resulting in the decrease in colour formation (Thiansilakul, Benjakul, & Shahidi, 2007). Ferrous chelating activity of SPHs and EDTA used as reference chelating agent, at different concentrations, are shown in Fig. 2d. The results indicated that SPHs are able to chelate Fe^{2+} ion. In a dose-dependent manner, SPH-An6 exhibited high activity ($86.85\% \pm 3.01$ at 5 mg mL^{-1}) than did SPH-A26 ($47.62\% \pm 2.75$ at 5 mg mL^{-1}) ($p < 0.05$). Chelating activity of SPH-An6 was higher than Flavourzyme hydrolyzed silver carp proteins (60% at 5 mg mL^{-1}) (Dong et al., 2008) and lower than

380 enzymatic sardinelle protein hydrolysates (between 54.82 and 78% at 0.25 mg mL⁻¹) (Ben
381 Khaled et al., 2014).

382 Transition metals such as Fe²⁺ and Cu²⁺ can catalyse the generation of reactive oxygen
383 species such as hydroxyl radical (OH°) and superoxide anion (O²⁻) (Stohs & Bagchi, 1995). In
384 fact, Fe²⁺ generates OH° by the Fenton reaction, when the lipid peroxidation chain reaction is
385 accelerated. The results indicate that protein hydrolysates can exhibit, to a various extent,
386 antioxidant ability by capturing ferrous ion or other ions. Therefore, chelation of metal ions
387 by peptides in hydrolysates would retard the oxidative reaction (Klompong, Benjakul,
388 Kantachote, Hayes, & Shahidi, 2008).

389

390 **3.3.5. ORAC assay**

391 The ORAC assay has been used to study the antioxidant capacity of many compounds
392 and food samples (Wu et al., 2004; Xu, Yuan, & Chang, 2007). ORAC values of SPHs at
393 different concentrations are presented in Fig. 2e. The results indicated that SPH-An6, with the
394 highest DH value, has a higher oxygen radical antioxidant capacity than SPH-A26 and that
395 this capacity increased with increasing concentration.

396

397 **3.4. Identification of peptides in SPH-A26 and SPH-An6**

398 Peptides in SPH-A26 and SPH-An6 were analysed by nESI-LC-MS/MS. A total of
399 approximately 800 peptides were identified. Fig. 3 shows the distribution in percentages of
400 the identified peptides according to their origin proteins. Main identified peptides derived
401 from myosin (31% in SPH-A26 and 43% in SPH-An6), followed by actin (12% and 17% in
402 SPH-A26 and SPH-An6, respectively). Peptide lengths from SPH-A26 and SPH-An6 are
403 between 6 and 26 amino acids.

404 Amino acid sequences of fifty low molecular weight peptides from each hydrolysate,
405 selected based on their easy intestinal absorption, as well as their protein origin, molecular
406 masses and modifications are presented in Tables 1 and 2. The length of these selected
407 peptides is between 6 and 10 amino acids. Indeed, it has been reported by Shimizu, Tsunogai,
408 & Arai (1997) the possibility of the passive diffusion of peptides of more than 4 amino acids,
409 especially hydrophobic peptides by transcytose. Other transport mechanisms, such as
410 paracellular diffusion, have been demonstrated for the transport of peptides of more than 4
411 amino acids (Shimizu, Tsunogai, & Arai, 1997).

412 The study of the hydrophobicity of selected peptides showed that they are mainly
413 hydrophobic, which improves their proper effect in the organism. Euston, Finnigan, & Hirst
414 (2001) reported that the wealth of protein hydrolysates with hydrophobic amino acids
415 facilitates their digestion and absorption in the intestine and improves their nutritional
416 properties compared to the intact protein. The most hydrophobic peptides are VIVIIIIGA,
417 ALDILDAA and ILLDLLIP in SPH-A26 and DVILPVPAF, IFAGLIQ, DVPGPVGIPF,
418 MILPVGAANF in SPH-An6.

419 By comparing peptides from the two hydrolysates, we found that YELPDGQVI and
420 FDKIEDMAM are present in both hydrolysates. Moreover, the sequences ISEELDHAL and
421 SEELDHALN from SPH-A26 and SPH-An6 share the same sequence SEELDHAL. Aspartic
422 acid (D) and glutamic acid (E) are the main amino acids present in the peptide sequences.
423 Table 3 reported some peptides sharing sequences with previously identified peptides.
424 Extended comparison revealed that LEE tripeptide found in the N-terminal sequences of P8
425 and P20 was also found in LEELEEELEGCE, an antioxidant peptide that was previously
426 purified from hydrolysate of bullfrog skin, *Rana catesbeiana* Shaw (Qian, Jung, & Kim,
427 2008). These three residues are also present in P7, P23 and P24 and could be implicated in the
428 peptide action. Similarly, the antioxidant peptide (EEEKNRLTKKTKKLT) derived from

429 bovine milk α -casein (Srinivas & Prakash, 2008) contain KLT at the C-terminal, which is also
430 present at the C-terminal of VIPELDGKLT (P16), and EEE at the N-terminal, which is also
431 localized at the N-terminal of EEELEAER (P27). Thus, these peptides could be probably
432 antioxidant. Furthermore, the three amino acid residues at the N-ter of P22 are also present at
433 the N-terminal of an antioxidant peptide VGPLSPT (Esteve, Marina, & García, 2015) and the
434 last three residues are localized at the C-terminal of MDGAP (Esteve, Marina, & García,
435 2015). These sequences have been reported as antioxidant peptides identified in olive seeds
436 (*Olea europaea*). Thus, P22 may have antioxidant activity. Previously, Lee, Cheng, Enomoto,
437 & Nakano (2006) identified an antioxidant peptide (TDY) from marine bivalve (*Mactra*
438 *veneriformis*) (Liu et al., 2015). This sequence is localized at the C-terminal of P5 which may
439 be considered as antioxidant peptide.

440 Potential ACE-inhibitor peptides from SPH-A26 (P4, P13, P18) were also detected, as
441 these peptides share the same first N-terminal residues of ACE inhibitors previously identified
442 (Kohmura et al., 1989; Miyoshi, Ishikawa, Kaneko, Fukui, & Tanaka, 1991; Yano, Suzuki, &
443 Funatsu, 1996; Pihlanto-Leppala, Koskinen, Piilola, Tupasela, & Korhonen, 2000). Further,
444 P32 contains GQF at the C-terminal, which is also found at the C-terminal of
445 YIEAVNKVSPRAGQE, an ACE inhibitor peptide from egg yolk (Zambrowicz et al., 2015).
446 Similarly, the first three residues of P34 (VAP) were previously identified as an ACE
447 inhibitor peptide (Maruyama, Mitachi, Tanaka, Tomizuka, & Suzuki, 1987). Extended
448 comparison revealed that sequences of P23, P24 and P25, from SPH-An6, have homology
449 with LRENNKLMLLELK, a bioactive peptide from bean (*Phaseolus vulgaris*) (Mojica,
450 Chen, & de Mejia, 2015), which exhibits antioxidant, ACE and DPP IV-inhibitory activities.
451 Indeed, the last three residues of this bioactive peptide are localized at the C-terminal of our
452 peptides and could be implicated in the peptide action. P10 has the same three first residues of

453 a dipeptidyl peptidase IV inhibitor, ILAP (Harnedey, O’Keeffe, & FitzGerald, 2015). Thus,
454 P10 may be hypoglycemic.

455

456 **3.5.ACE-inhibitory and antioxidant activities of synthesized peptides**

457 Eight peptides from SPH-A26 and seven peptides from SPH-An6 were selected for
458 chemical synthesis (Table 4). The selection was based on peptides’ homologies with
459 previously identified peptides (Biopep data bank) as well as peptides’ length. In fact, it is well
460 known, that short peptides can be efficiently absorbed through the intestine in an active form,
461 more readily in comparison to larger peptides (He, Liu, & Ma, 2013). Further, short peptides
462 generally are more resistant to gastrointestinal digestion and serum peptidases than larger
463 peptides.

464

465 **3.5.1. ACE-inhibitory activity**

466 The ACE-inhibitory activity of synthesized peptides was investigated at a concentration
467 of 0.25 mM (Fig. 4). The results clearly show that all synthesized peptides displayed ACE-
468 inhibitory activity and P9 (NVPVYEGY) from SPH-A26 exhibited the highest activity
469 ($57.02\% \pm 0.54$), while in SPH-An6, P21 (ITALAPSTM) displayed the highest activity
470 ($52.07\% \pm 1.88$) followed by P31 (SLEAQAEKY) ($33.11\% \pm 2.22$). The other peptides
471 weakly inhibited ACE-activity *in vitro*.

472 NVPVYEGY showed IC_{50} value of 0.21 ± 0.003 mM, while ITALAPSTM and
473 SLEAQAEKY showed IC_{50} values of 0.229 ± 0.01 mM and 0.406 ± 0.02 mM, respectively.
474 The IC_{50} values of these peptides were higher than that of VIEKYP, an ACE-inhibitor peptide
475 from mushroom *Tricholoma giganteum* ($IC_{50}= 0.1 \mu\text{M}$) (Murray & FitzGerald, 2007) and
476 KVREGT ($IC_{50}= 9.1 \mu\text{M}$), a peptide derived from hen ovotransferrin as pro-drug (Lee,
477 Cheng, Enomoto, & Nakano, 2006). Higher values of IC_{50} were reported by Pihlanto-Leppala,

478 Koskinen, Piilola, Tupasela, & Korhonen (2000) for the fragment of bovine beta-
479 lactoglobulin (VFK) ($IC_{50}= 1.029$ mM) and by Katayama et al. (2008) who identified an ACE
480 inhibitor peptide (EKERERQ) from porcine skeletal muscle troponin with an IC_{50} of 0.552
481 mM.

482 The synthesized peptides which exhibited high ACE-inhibitory activity contained a high
483 content of hydrophobic amino acid residues. Among them, SLEAQAEKY possess a Ser
484 residue at the N-terminal and Tyr at the C-terminal positions. Although the structure-activity
485 relation ship of ACE inhibitory peptides has not been fully established, it seems that binding
486 to ACE is strongly influenced by the C-terminal tripeptide sequence. Indeed, peptides
487 containing hydrophobic amino acid residues, such as Pro, Phe and Tyr, at the three C-terminal
488 positions are potent inhibitors (Murray & FitzGerald, 2007). In this respect, the high activity
489 of QIEDFKEAF could be attributed in particular to Phe at the C-terminal position, one of the
490 most favourable C-terminal amino acid for binding to the ACE active sites (Gobbetti,
491 Ferranti, Smacchi, Goffredi, & Addeo, 2000).

492

493 **3.5.2. Antioxidant activities of synthesized peptides**

494 The antioxidant activities of synthesized peptides were also investigated. Fig. 5a shows
495 the DPPH radical-scavenging activity of synthesized peptides at a concentration of 1 mM. All
496 peptides were able to scavenge DPPH. The activities of the most active peptides (P1, P5, P6,
497 P8 and P9 from SPH-A26 and P23 and P33 from SPH-An6) were ranged from 30% to 48%.
498 Their IC_{50} values were determined and presented in Table 5. The results indicated that
499 GTEDELDKY (P33) exhibited the highest radical-scavenging activity ($IC_{50}= 1.32 \pm 0.01$),
500 followed by NVPVYEGY (P9) ($IC_{50}= 1.41 \pm 0.03$) and AGRDLTDY (P5) ($IC_{50}= 1.54 \pm$
501 0.01). These IC_{50} values were lower than that of LEELEEELEGCE ($IC_{50}=16.1$ mM), an
502 antioxidant peptide from bullfrog skin hydrolysate (Qian, Jung, & Kim, 2008). On the other

503 hand, Liu et al. (2015) identified the peptides TDY and LYEGY with IC_{50} of 0.14 mM and
504 0.217, respectively, from an enzymatic hydrolysate of *Macrura veneriformis*. P21
505 (ITALAPSTM), which displayed high ACE-inhibitory activity was found to show low DPPH
506 radical-scavenging activity. The results obtained suggested that some peptides within
507 sardinelle protein hydrolysates were significantly strong radical scavengers.

508 Fig. 5b shows the reducing power activities of all synthesized peptides at a concentration
509 of 0.3 mM compared with BHA as standard. P9 (NVPVYEGY) displayed the highest
510 reducing power activity, followed by P5 (AGRDLTDY) and P31 (SLEAQAEKY).

511 The antioxidant activities of synthesized peptides measured by β -carotene bleaching at a
512 concentration of 1 mM are reported in Fig. 5c and the IC_{50} values were determined and
513 presented in Table 5. All synthesized peptides, except P31, showed antioxidant activities.
514 Results indicate that from SPH-A26, P12 (KDIDDLELT) and P14 (ISEELDHAL) showed the
515 highest ability to prevent bleaching of β -carotene ($IC_{50}= 0.22 \pm 0.01$ and $0.34 \text{ mM} \pm 0.01$,
516 respectively). From SPH-An6, P19 (EVIEIQ) is the most active peptide ($IC_{50}= 0.31 \text{ mM} \pm$
517 0.05).

518 Moreover, ORAC values of synthesized peptides at a concentration of 0.25 mM are
519 presented in Fig. 5d. The results indicated that P5, P9, and P14 from SPH-A26 and P21, P29,
520 P31, and P33 from SPH-An6 displayed high peroxy radical scavenging activity. Qian, Jung,
521 & Kim (2008) purified from the hydrolysate of bullfrog skin *Rana catesbeiana* Shaw an
522 antioxidant peptide, LEELEEELEGCE. This peptide exhibits peroxy radical scavenging
523 activity with an $IC_{50}=32.6 \text{ mM}$.

524 Results showed that P5, P9, and P33, which contain Tyr at their C-terminal displayed
525 high DPPH radical-scavenging, reducing power and peroxy radical scavenging activities. The
526 antioxidant activities of these peptides may result from the Tyr residue localized at C-terminal
527 position. Furthermore, P14 and P29, which displayed high peroxy radical scavenging activity

528 contained His in their sequences, and P21, which has Met at the C-terminal, displayed high β -
529 caroten bleaching activity. The presence of His and Met in the sequences of these peptides
530 could explain their action. In fact, Dávalos, Miguel, Bartolomé, & López-Fandino (2004)
531 reported that among the amino acids, Trp, Tyr and Met showed the highest antioxidant
532 activity, followed by Cys, His and Phe. The antioxidant activity of histidine-containing
533 peptides has been reported and attributed to the chelating and lipid radical-trapping ability of
534 the imidazole ring (Murase, Nagao, & Terao, 1993; Park, Jung, Nam, Shahidi, & Kim, 2001;
535 Uchida & Kawakishi, 1992).

536

537 **4. Conclusion**

538 In the present study, SPHs obtained by fermentation were found to display antioxidant
539 and ACE-inhibitory activities. The hydrolysates were analysed using ESI-LC-MS/MS and
540 peptide sequences were determined. Some of the identified peptides share a partial sequence
541 homology with previously identified bioactive peptides. Fifteen selected peptides were
542 synthesized and their ACE-inhibitory and antioxidant activities *in vitro* were studied.
543 NVPVYEGY and ITALAPSTM peptides showed the highest ACE inhibitory activity with
544 IC_{50} values of 0.21 ± 0.003 and 0.229 ± 0.01 mM, respectively. Regarding the antioxidant
545 capacity, NVPVYEGY and GTEDELDKY peptides displayed the highest activities.

546 Therefore, this research provided a scientific basis for the preparation by fermentation
547 process of antioxidant and hypotensive peptides from sardinelle protein hydrolysates that
548 could be utilized in food systems as a natural additive possessing antioxidative and preventing
549 hypertension properties. Further studies will be needed to evaluate the *in vivo* activities of the
550 identified peptides.

551

552 **Acknowledgements**

553 This work was funded by grant AGL2014-57367-R from MINECO and FEDER funds
554 as well as the Ministry of Higher Education and Scientific Research-Tunisia and the
555 Emerging Research Group Grant from Generalitat Valenciana in Spain (GV/2015/138).
556 JAEDOC-CSIC postdoctoral contract of L.M. cofunded by the European Social Found is also
557 acknowledged. LC-MS/MS analysis was carried out in the SCSIE University of Valencia
558 Proteomics Unit (Spain), a member of ISCIII ProteoRed Proteomics Platform.

559

560 **References**

561 Abdelhedi, O., Jridi, M., Jemil, I., Mora, L., Toldrá, F., Aristoy, M. C., et al. (2016).
562 Combined biocatalytic conversion of smooth hound viscera: Protein hydrolysates elaboration
563 and assessment of their antioxidant, anti-ACE and antibacterial activities. *Food Research*
564 *International*, 86, 9-23.

565 Agrebi, R., Haddar, A., Hajji, M., Frikha, F., Manni, L., Jellouli, K., et al. (2009). Fibrinolytic
566 enzymes from a newly isolated marine bacterium *Bacillus subtilis* A26: characterization and
567 statistical media optimization. *Canadian Journal of Microbiology*, 55, 1049-1061.

568

569 Agrebi, R., Hmidet, N., Hajji, M., Ktari, N., Haddar, A., Fakhfakh-Zouari, N., et al. (2010).
570 Fibrinolytic serine-protease from *Bacillus amyloliquefaciens* An6 grown on *Mirabilis jalapa*
571 tuber powders: Production, partial purification and biochemical characterization. *Applied*
572 *Biochemistry and Biotechnology*, 162, 75-88.

573

574 Alemán, A., Pérez-Santin, E., Bordenave-Juchereau, S., Arnaudin, I., Gomez-Guillén, M. C.,
575 & Montero, P. (2011). Squid gelatin hydrolysates with antihypertensive, anticancer and
576 antioxidant activity. *Food Research International*, 44, 1044-1051.

577

578 AOAC (2000). Official Methods of Analysis, 17th edn. Association of Official Analytical
579 Chemists, Washington.
580

581 Ben Khaled, H., Ktari, N., Ghorbel-Bellaaj, O., Jridi, M., Lassoued, I., & Nasri, M. (2014).
582 Composition, functional properties and *in vitro* antioxidant activity of protein hydrolysates
583 prepared from sardinelle (*Sardinella aurita*) muscle. *Journal of Food Science and*
584 *Technology*, 51, 622-633.
585

586 Bersuder, P., Hole, M., & Smith, G. (1998). Antioxidants from a heated histidine–glucose
587 model system. I. Investigation of the antioxidant role of histidine and isolation of antioxidants
588 by high performance liquid chromatography. *Journal of the American Oil Chemists' Society*,
589 75, 181-187.
590

591 Bkhairia, I., Ben Slama-Ben Salem, R., Nasri, R., Jridi, M., Ghorbel, S., & Nasri, M. (2016).
592 *In vitro* antioxidant and functional properties of protein hydrolysates from golden grey mullet
593 prepared by commercial, microbial and visceral proteases. *Journal of Food Science and*
594 *Technology*, DOI 10.1007/s13197-016-2200-5.
595

596 Chakka, A. K., Elias, M., Jini, R., Sakhare, P. Z., & Bhaskar, N. (2015). *In-vitro* antioxidant
597 and antibacterial properties of fermentatively and enzymatically prepared chicken liver
598 protein hydrolysates. *Journal of Food Science and Technology*, 52, 8059-8067.
599

600 Chi, C. F., Hu, F. Y., Wang, B., Ren, X. J., Deng, S. G., & Wu, C. W. (2014). Purification
601 and characterization of three antioxidant peptides from protein hydrolyzate of croceine
602 croaker (*Pseudosciaena crocea*) muscle. *Food Chemistry*, 168, 662-667.

603

604 Cooper, W. O., Hernandez-Diaz, S., Arbogast, P. G., Dudley, J. A., Dyer, S., Gideon, P. S., et
605 al. (2006). Major congenital malformations after first-trimester exposure to ACE inhibitors.
606 *New England Journal of Medicine*, 354, 2443-2451.

607

608 Connolly, T. M., Condra, C., Feng, D. M., Cook, J. J., Stranieri, M. T., Reilly, C. F., et al.
609 (1994). Species variability in platelet and other cellular responsiveness to thrombin receptor-
610 derived peptides. *Thrombosis and Haemostasis*, 72, 627-633.

611

612 Dávalos, A., Miguel, M., Bartolomé, B., & López-Fandino, R. (2004). Antioxidant activity of
613 peptides derived from egg white proteins by enzymatic hydrolysis. *Journal of Food*
614 *Protection*, 67, 1939-1944.

615

616 Dávalos, A., Gómez-Cordovés, C., & Bartolomé, B. (2004). Extending applicability of the
617 oxygen radical absorbance capacity (ORAC–Fluorescein) assay. *Journal of Agricultural and*
618 *Food Chemistry*, 52, 48-54.

619

620 Dinis, T. C., Maderia, V. M., & Almeida, L. M. (1994). Action of phenolic derivatives
621 (acetaminophen, salicylate, and 5-aminosalicylate) as inhibitors of membrane lipid
622 peroxidation and as peroxy radical scavengers. *Archives Biochemistry Biophysics*, 315, 161-
623 169.

624

625 Dong, S., Zeng, M., Wang, D., Liu, Z., Zhao, Y., & Yang, H. (2008). Antioxidant and
626 biochemical properties of protein hydrolysates prepared from silver carp
627 (*Hypophthalmichthys molitrix*). *Food Chemistry*, 107, 1485-1493.

628

629 Escudero, E., Mora, L., Fraser, P. D., Aristoy, M.C., Arihara, K., & Toldra, F. (2013).
630 Purification and identification of antihypertensive peptides in Spanish dry-cured ham. *Journal*
631 *of Proteomics*, 78, 499-507.

632

633 Esteve, C., Marina, M. L., & García, M. C. (2015). Novel strategy for the revalorization of
634 olive (*Olea europaea*) residues based on the extraction of bioactive peptides. *Food Chemistry*,
635 167, 272-280.

636

637 Euston, S. R., Finnigan, S. R., & Hirst, R. L. (2001). Heat-induced destabilization of oil-in-
638 water emulsions formed from hydrolyzed whey protein. *Journal of Agricultural and Food*
639 *Chemistry*, 49, 5576-5583.

640

641 Fakhfakh, N., Ktari, N., Siala, R., & Nasri, M. (2013). Wool-waste valorization: production of
642 protein hydrolysate with high antioxidative potential by fermentation with a new keratinolytic
643 bacterium, *Bacillus pumilus* A1. *Journal of Applied Microbiology*, 115, 424-433.

644

645 Garber, D. W., Handattu, S. P., Datta, G., Mishra, V. K., Gupta, H., White, R., et al. (2006).
646 Atherosclerosis and vascular disease: effects of peptide mimetics of apolipoproteins. *Current*
647 *Pharmaceutical Biotechnology*, 7, 235-240.

648

649 Gobbetti, M., Ferranti, P., Smacchi, E., Goffredi, F., & Addeo, F. (2000). Production of
650 angiotensin-I-converting-enzyme-inhibitory peptides in fermented milks started by
651 *Lactobacillus delbrueckii* subsp. *bulgaricus* SS1 and *Lactococcus lactis* subsp. *cremoris* FT4.
652 *Applied and Environmental Microbiology*, 66, 3898-3904.

653

654 Gu, R. Z., Li, C. Y., Liu, W. Y., Yi, W. X., & Cai, M. Y. (2011). Angiotensin I-converting
655 enzyme inhibitory activity of low-molecular-weight peptides from Atlantic salmon (*Salmo*
656 *salar* L.) skin. *Food Research International*, *44*, 1536-1540.

657

658 Harnedy, P. A., O’Keeffe, M. B., & FitzGerald, R. J. (2015). Purification and identification of
659 dipeptidyl peptidase (DPP) IV inhibitory peptides from the macroalga *Palmaria palmata*.
660 *Food Chemistry*, *172*, 400-406.

661

662 Harris, T., Cook, E. F., Kannel, W., Schatzkin, A., & Goldman, L. (1985). Blood pressure
663 experience and risk of cardiovascular disease in the elderly. *Hypertension*, *7*, 118–124.

664

665 He, H. L., Liu, D., & Ma, C. B. (2013). Review on the angiotensin-I-converting enzyme
666 (ACE) inhibitor peptides from marine proteins. *Applied Biochemistry and Biotechnology*, *169*,
667 738–749.

668

669 Hernandez-Ledesma, B., Amigo, L., Recio, I., & Bartolome, B. (2007). ACE-inhibitory and
670 radical scavenging activity of peptides derived from beta-lactoglobulin f(19-25). Interactions
671 with ascorbic acid. *Journal of Agricultural and Food Chemistry*, *55*, 3392-3397.

672

673 Houston, M. C. (2005). Nutraceuticals, vitamins, antioxidants, and minerals in the prevention
674 and treatment of hypertension. *Progress in Cardiovascular Diseases*, *47*, 396-449.

675

676 Ishida, A., Shigeri, Y., Tatsu, Y., Uegaki, K., Kameshita, I., Okuno, S., et al. (1998). Critical
677 amino acid residues of AIP, a highly specific inhibitory peptide of calmodulin-dependent
678 protein kinase II. *FEBS Letters*, *427*, 115-118.

679

680 Jemil, I., Jridi, M., Nasri, R., Ktari, N., Ben Slama-Ben Salem, R., Hajji, M., et al. (2014).
681 Functional, antioxidant and antibacterial properties of protein hydrolysates prepared from fish
682 meat fermented by *Bacillus subtilis* A26. *Process Biochemistry*, *49*, 963–972.

683

684 Jemil, I., Abdelhedi, O., Nasri, R., Mora, L., Marrekchi, R., Jamoussi, K., et al. (2016).
685 Hypolipidemic, antiobesity and cardioprotective effects of fermented protein hydrolysates
686 from sardinelle (*Sardinella aurita*) in high-fat and fructose diet fed Wistar rats. *Life Sciences*,
687 [doi:10.1016/j.lfs.2016.07.012](https://doi.org/10.1016/j.lfs.2016.07.012)

688

689 Jiménez-Escrig, A., Alaiz, M., Vioque, J., & Rupérez, P. (2010). Health-promoting activities
690 of ultra-filtered okara protein hydrolysates released by *in vitro* gastrointestinal digestion:
691 identification of active peptide from soybean lipoxygenase. *European Food Research and*
692 *Technology*, *230*, 655-663.

693

694 Katayama, K., Anggraeni, H. E., Mori, T., Ahmed, A. M., Kawahara, S., Sugiyama, M., et al.
695 (2008). Porcine skeletal muscle troponin is a good source of peptides with angiotensin-I
696 converting enzyme inhibitory activity and antihypertensive effects in spontaneously
697 hypertensive rats. *Journal of Agricultural and Food Chemistry*, *56*, 355-360.

698

699 Kleekayai, T., Harnedy, P. A., O’Keeffe, M. B., Poyarkov, A. A., CunhaNeves, A. A.,
700 Suntornsuk, W. W., et al. (2015). Extraction of antioxidant and ACE inhibitory peptides from
701 Thai traditional fermented shrimp pastes. *Food Chemistry*, *176*, 441-447.
702

703 Klompong, V., Benjakul, S., Kantachote, D., Hayes, K. D., & Shahidi, F. (2008).
704 Comparative study on antioxidative activity of yellow stripe trevally protein hydrolysate
705 produced from Alcalase and Flavourzyme. *International Journal of Food Science and*
706 *Technology*, *43*, 1019-1026.
707

708 Kohmura, M., Nio, N., Kubo, K., Minoshimo, Y., Munekata, E., & Ariyoshi, Y. (1989).
709 Inhibition of angiotensin-converting enzyme by synthetic peptides of human beta-casein.
710 *Agricultural and Biological Chemistry*, *53*, 2107-2114.
711

712 Koleva, I. I., Van Beek, T. A., Linssen, J. P. H., De Groot, A., & Evstatieva, L. N. (2002).
713 Screening of plant extracts for antioxidant activity: a comparative study on three testing
714 methods. *Phytochemical Analysis*, *13*, 8-17.
715

716 Kumazawa, S., Taniguchi, M., Suzuki, Y., Shimura, M., Kwon, M. S., & Nakayama, T.
717 (2002). Antioxidant activity of polyphenols in carob pods. *Journal of Agricultural and Food*
718 *Chemistry*, *50*, 373-377.
719

720 Lassoued, I., Mora, L., Nasri, R., Aydi, M., Toldrá, F., Aristoy, M. C., et al. (2015).
721 Characterization, antioxidative and ACE inhibitory properties of hydrolysates obtained from
722 thornback ray (*Raja clavata*) muscle. *Journal of Proteomics*, *128*, 458-468.
723

724 Lavoie, J. L., & Sigmund, C. D. (2003). Minireview: Overview of the renin-angiotensin
725 system; An endocrine and paracrine system. *Endocrinology*, *144*, 2179-2183.
726

727 Liu, X., Zhang, M., Jia, A., Zhang, Y., Zhu, H., Zhang, C., et al. (2013). Purification and
728 characterization of angiotensin I converting enzyme inhibitory peptides from jellyfish
729 *Rhopilema esculentum*. *Food Research International*, *50*, 339-343.
730

731 Liu, R., Zheng, W., Li, J., Wang, L., Wu, H., Wang, X., et al. (2015). Rapid identification of
732 bioactive peptides with antioxidant activity from the enzymatic hydrolysate of *Macrura*
733 *veneriformis* by UHPLC-Q-TOF mass spectrometry. *Food Chemistry*, *167*, 484-489.
734

735 Lee, N. Y., Cheng, J. T., Enomoto, T., & Nakano, Y. (2006). One peptide derived from hen
736 ovotransferrin as pro-drug to inhibit angiotensin converting enzyme. *Journal of Food and*
737 *Drug Analysis*, *14*, 31-35.
738

739 Maruyama, S., Mitachi, H., Tanaka, H., Tomizuka, N., & Suzuki, H. (1987). Angiotensin-I
740 converting enzyme inhibitory activity of the C-terminal hexapeptide of alpha-casein.
741 *Agricultural and Biological Chemistry*, *51*, 2557-2561.
742

743 Mito, K., Fujii, M., Kuwahara, M., Matsumura, N., Shimizu, T., Sugano, S., et al. (1996).
744 Antihypertensive effect of angiotensin I-converting enzyme inhibitory peptides derived from
745 hemoglobin. *European Journal of Pharmacology*, *304*, 93-98.
746

747 Miyoshi, S., Ishikawa, H., Kaneko, T., Fukui, F., & Tanaka, H. (1991). Structure and activity
748 of angiotensin-converting enzyme inhibitors in alpha-zein hydrolysate. *Agricultural and*
749 *Biological Chemistry*, *55*, 1313-1318.

750

751 Mojica, L., Chen, K., & de Mejia, E. G. (2015). Impact of commercial precooking of common
752 bean (*Phaseolus vulgaris*) on the generation of peptides, after pepsin-pancreatin hydrolysis,
753 capable to inhibit dipeptidyl peptidase-IV. *Journal of Food Science*, *80*, 188-198.

754

755 Mora, L., Escudero, E., Aristoy, M. C., & Toldrá, F. (2015). A peptidomic approach to study
756 the contribution of added casein proteins to the peptide profile in Spanish dry-fermented
757 sausages. *International Journal of Food Microbiology*, *212*, 41–48.

758

759 Morales-Medina, R., Tamm, F., Guadix, A. M., Guadix, E. M., & Drusch, S. (2016).
760 Functional and antioxidant properties of hydrolysates of sardine (*S. pilchardus*) and horse
761 mackerel (*T. mediterraneus*) for the microencapsulation of fish oil by spray-drying, *Food*
762 *Chemistry*, *194*, 1208-1216.

763

764 Murase, H., Nagao, A., & Terao, J. (1993). Antioxidant and emulsifying activity of N-(long-
765 chain-acyl) histidine and N-(long-chain-acyl) carnosine. *Journal of Agricultural and Food*
766 *Chemistry*, *41*, 1601–1604.

767

768 Murray, B. A., & FitzGerald, R. J. (2007). Angiotensin converting enzyme inhibitory peptides
769 derived from food proteins: biochemistry, bioactivity and production. *Current*
770 *Pharmaceutical Design*, *13*, 773-791.

771

772 Nasri, R., Younes, I., Jridi, M., Trigui, M., Bougatef, A., Nedjar-Arroume, N., et al. (2013).
773 ACE inhibitory and antioxidative activities of goby (*Zosterisessor ophiocephalus*) fish
774 protein hydrolysates : Effect on meat lipid oxidation. *Food Research International*, 54, 552–
775 561.

776

777 Nasri, R., Jridi, M., Lassoued, I., Jemil, I., Ben Slama-Ben Salem, R., Nasri, M., et al. (2014).
778 The influence of the extent of enzymatic hydrolysis on antioxidative properties and ACE-
779 inhibitory activities of protein hydrolysates from goby (*Zosterisessor ophiocephalus*) muscle.
780 *Applied Biochemistry and Biotechnology*, 173, 1121-1134.

781

782 Nielsen, P. M., Petersen, D., & Dambmann, C. (2001). Improved method for determining
783 food protein degree of hydrolysis. *Journal of Food Science*, 66, 642-646.

784

785 Park, P. J., Jung, W. K., Nam, K. S., Shahidi, F., & Kim, S. K. (2001). Purification and
786 characterization of antioxidative peptides from protein hydrolysate of lecithin free egg yolk.
787 *Journal of the American Oil Chemists' Society*, 78, 651-656.

788

789 Pihlanto-Leppala, A., Koskinen, P., Piilola, K., Tupasela, T., & Korhonen, H. (2000).
790 Angiotensin I-converting enzyme inhibitory properties of whey protein digests: concentration
791 and characterization of active peptides. *Journal of Dairy Research*, 67, 53-64.

792

793 Qian, Z. J., Jung, W. K., & Kim, S. K. (2008). Free radical scavenging activity of a novel
794 antioxidative peptide purified from hydrolysate of bullfrog skin, *Rana catesbeiana* Shaw.
795 *Bioresource Technology*, 99, 1690-1698.

796

797 Ringseis, R., Motthes, B., Lehmann, V., Becker, K., Schöps, R., Ulbrich-Hofmann, R., et al.
798 (2005). Peptides and hydrolysates from casein and soy protein modulate the release of
799 vasoactive substances from human aortic endothelial cells. *Biochimica et Biophysica Acta-*
800 *General Subjects*, 1721, 89-97.

801

802 Saiga, A., Tanabe, S., & Nishimura, T. (2003). Antioxidant activity of peptides obtained from
803 porcine myofibrillar proteins by protease treatment. *Journal of Agricultural and Food*
804 *Chemistry*, 51, 3661-3667.

805

806 Salampessy, J., Reddy, N., Kailasapathy, K., & Phillips, M. (2015). Functional and potential
807 therapeutic ACE-inhibitory peptides derived from bromelain hydrolysis of trevally proteins.
808 *Journal of Functional Foods*, 14, 716-725.

809

810 Salvetti, A. (1990). Newer ACE inhibitors. A look at the future. *Drugs*, 40, 800-828.

811

812 Sentandreu, M. A., & Toldrá, F. (2006). A rapid, simple and sensitive fluorescence method
813 for the assay of angiotensin-I converting enzyme. *Food Chemistry*, 97, 546-554.

814

815 Silveira, S. T., Martínez-Maqueda, D., Recio, I., & Hernández-Ledesma, B. (2013).
816 Dipeptidyl peptidase-IV inhibitory peptides generated by tryptic hydrolysis of a whey protein
817 concentrate rich in β -lactoglobulin. *Food Chemistry*, 141, 1072-1077.

818

819 Shimada, K., Fujikawa, K., Yahara, K., & Nakamura, T. (1992). Antioxidative properties of
820 xanthan on the antioxidation of soybean oil in cyclodextrin emulsion. *Journal of Agricultural*
821 *and Food Chemistry*, 40, 945-948.

822

823 Shimizu, M., Tsunogai, M., & Arai, S. (1997). Transepithelial transport of oligopeptides in
824 the human intestinal cell, Caco-2. *Peptides*, 18, 681-687.

825

826 Sudhakar, S., & Abdul Nazeer, R. (2015). Preparation of potent antioxidant peptide from
827 edible part of shortclub cuttlefish against radical mediated lipid and DNA damage. *LWT -*
828 *Food Science and Technology*, 64, 593-601.

829

830 Srinivas, S., & Prakash, V. (2008). Effect of cosolvents on the stabilization of bioactive
831 peptides from bovine milk α -casein. *Protein and Peptide Letters*, 15, 371-376.

832

833 Stohs, S. J., & Bagchi, D. (1995). Oxidative mechanisms in the toxicity of metal ions. *Free*
834 *Radical Biology and Medicine*, 18, 321-336.

835

836 Suryakanth, D. A., Rafiq, M., Azeemuddin, M., Vis-wanatha, G. L., Jagadeesh, M., Sandeep
837 Rao, K. S., et al. (2012). Free radical scavenging and hepatoprotective activity of HD-03/ES
838 in experimental models. *Journal of Experimental and Integrative Medicine*, 2, 161-166.

839

840 Thiansilakul, Y., Benjakul, S., & Shahidi, F. (2007). Compositions, functional properties and
841 antioxidative activity of protein hydrolysates prepared from round scad (*Decapterus*
842 *maruadsi*). *Food Chemistry*, 103, 1385-1394.

843

844 Tomatsu, M., Shimakage, A., Shinbo, M., Yamada, S., & Takahashi, S. (2013). Novel
845 angiotensin I-converting enzyme inhibitory peptides derived from soya milk. *Food Chemistry*,
846 136, 612-616.

847

848 Toopcham, T., Roytrakul, S., & Yongsawatdigul, J. (2015). Characterization and
849 identification of angiotensin I-converting enzyme (ACE) inhibitory peptides derived from
850 tilapia using *Virgibacillus halodenitrificans* SK1-3-7 proteinases. *Journal of Functional*
851 *Foods, 14*, 435-444.

852

853 Torino, M. I., Limón, R. I., Martínez-Villaluenga, C., Mäkinen, S., Pihlanto, A., Vidal-
854 Valverde, C., et al. (2013). Antioxidant and antihypertensive properties of liquid and solid
855 state fermented lentils. *Food Chemistry, 136*, 1030-1037.

856

857 Tsopmo, A., Romanowski, A., Banda, L., Lavoie, J. C., & Jensen, H. (2011). Novel anti-
858 oxidative peptides from enzymatic digestion of human milk. *Food Chemistry, 126*, 1138-
859 1143.

860

861 Uchida, K., & Kawakishi, S. (1992). Sequence-dependant reactivity of histidine containing
862 peptides with copper(II)/ascorbate. *Journal of Agricultural and Food Chemistry, 40*, 13-16.

863

864 Wu, X. L., Beecher, G. R., Holden, J. M., Haytowitz, D. B., Gebhardt, S. E., & Prior, R. I.
865 (2004). Lipophilic and hydrophilic antioxidant capacities of common foods in the United
866 States. *Journal of Agricultural and Food Chemistry, 52*, 4026-4037.

867

868 Xu, B. J., Yuan, S. H., & Chang, S. K. C. (2007). Comparative analyses of phenolic
869 composition and antioxidant capacity of cool season legumes with others elected food
870 legumes. *Journal of Food Science, 72*, 167-177.

871

872 Yano, S., Suzuki, K., & Funatsu, G. (1996). Isolation from alpha-zein of thermolysin peptides
873 with angiotensin I-converting enzyme inhibitory activity. *Bioscience, Biotechnology, and*
874 *Biochemistry*, 60, 661-663.

875

876 Yeh, C. H., Peng, H. C., Yih, J. B., & Huang, T. F. (1995). A new short chain RGD-
877 containing disintegrin, accutin, inhibits the common pathway of human platelet aggregation.
878 *Biochimica et Biophysica Acta*, 1425, 493-504.

879

880 Yildirim, A., Mavi, A., & Kara, A. A. (2001). Determination of antioxidant and antimicrobial
881 activities of *Rumex crispus* L. extracts. *Journal of Agricultural and Food Chemistry*, 49,
882 4083-4089.

883

884 Zambrowicz, A., Pokora, M., Setner, B., Dąbrowska, A., Szoltyśnik, M., Babij, K., et al.
885 (2015). Multifunctional peptides derived from an egg yolk protein hydrolysate: isolation and
886 characterization. *Amino Acid*, 47, 369-380.

887

888

889

890

891

892

893

894

895

896

897 **Table 1**

898 Selection of peptides identified from SPH-A26 using nESI-LC-MS/MS.

Peptide sequence	Protein origin	Calculated Molecular mass (Da)	Modifications
LDDFKL	Calcium uniporter protein	749,39	
VIVIIIIGA	Uncharacterized permease C1683.05	796,54	
ALDILDAA	Tegument protein UL47	800,43	
IDFGFDL	DNA polymerase	825,39	
ISNIEDF	REVERSED Uncharacterized metallohydrolase MJ0457	836,39	
EAPGPINF	Myosin regulatory light chain 2	843,41	
LNPTNASH	Glycerol-3-phosphate dehydrogenase [NAD(+)]	853,39	Deamidated(N)@2
GDEGGFAPN	Beta-enolase	862,34	
FTIVVAIT	REVERSED CASP-like protein F16	862,51	
GFNPPDL	Sarcoplasmic/endoplasmic reticulum calcium ATPase 1	873,39	
AGYDDIQAG	Galactose-1-phosphate uridylyltransferase	908,39	
ILLDLLIP	ATP-dependent protease ATPase subunit HslU	908,59	
AGRDLTDY	Actin, alpha skeletal muscle	909,42	
LIENDEAL	Acetylglutamate kinase	915,45	Oxidation(M)@12
TALEEAEGT	Myosin heavy chain, fast skeletal muscle	919,41	
IEEELGDK	Enolase	931,45	
IKEAPGPIN	Myosin regulatory light chain 2	937,52	
NVPVYEGY	Actin, alpha skeletal muscle	939,43	
EAPGPINFT	Myosin regulatory light chain 2	944,46	
LEEEVGAAK	REVERSED Dihydroxy-acid dehydratase	944,52	
IEEEVKAK	Myosin heavy chain, fast skeletal muscle	944,52	
IAAPELEPL	Titin	951,53	
NVPIYEGY	Actin, alpha skeletal muscle	953,45	
ILAADESTGS	Fructose-bisphosphate aldolase A	962,45	
IEFNVLQ	REVERSED Exportin-5	975,53	Deamidated(N)@4
VFKDLFDP	Creatine kinase M-type	979,50	
YETDAIQR	Myosin heavy chain, fast skeletal muscle	994,47	
NHDPVVGDR	Glycogen phosphorylase, brain form	1007,48	
ADYEDYIK	Glycogen phosphorylase, muscle form	1015,45	
GEVEDLMID	Myosin heavy chain, fast skeletal muscle	1019,45	
ISEELDHAL	Tropomyosin alpha-1 chain	1025,50	
GFEDYVEGL	Myosin light chain 1, skeletal muscle isoform	1027,45	

YELPDGQVI	Actin, alpha skeletal muscle	1032,51	
RVAPEEHPT	Actin, alpha skeletal muscle	1034,51	
GTNDETERQ	RWD domain-containing protein 2B	1048,44	
KDIDDLELT	Myosin heavy chain, fast skeletal muscle	1060,53	
IVDVPVGEEL	ATP synthase subunit alpha, mitochondrial	1068,57	
TYDDYVEGL	Myosin light chain 3, skeletal muscle isoform	1073,45	
ATEDELDKY	Tropomyosin alpha-1 chain	1082,48	
VIPELDGKLT	Glyceraldehyde-3-phosphate dehydrogenase	1083,62	
GYPDKIIIIGM	Beta-enolase	1105,58	
FDKIEDMAM	Myosin heavy chain, fast skeletal muscle	1114,47	Oxidation(M)@9
TIHHLGPRQS	Collagen alpha-1(XXVII) chain	1120,63	
ILPDGDHDLK	Fructose-bisphosphate aldolase A	1121,57	
GTYYDYVEGL	Myosin light chain 3, skeletal muscle isoform	1130,48	
AINDPFIDLD	Glyceraldehyde-3-phosphate dehydrogenase, cytosolic	1131,54	
ILENNEALEL	Beta-enolase	1157,58	Deamidated(N)@4
FGYSNRVVDL	Glyceraldehyde-3-phosphate dehydrogenase	1169,57166	Deamidated(N)@5
IDFDEFLKM	Troponin C, skeletal muscle	1172,54	Oxidation(M)@9
TWYDNEFGY	Glyceraldehyde-3-phosphate dehydrogenase	1193,47	

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915 **Table 2**

916 Selection of peptides identified from SPH-An6 using LC-MS/MS.

Peptide sequence	Protein origin	Calculated Molecular mass (Da)	Modifications
EVIEIQ	Citron Rho-interacting kinase	729,39	
IFAGLIQ	REVERSED Probable serine/threonine-protein kinase gdt9	760,45	
DELKLF	Parvalbumin alpha	763,41	
ELAKTAD	REVERSED Serine/arginine-rich splicing factor RS31	875,42	
LEEAGGATAA	Myosin heavy chain, fast skeletal muscle	888,42	
ITALAPSTM	Actin, alpha skeletal muscle	903,47	
LTALAPSTM	Actin-1	903,47	
VGPLGRSGAP	REVERSED Collagen alpha-1(VII) chain	909,50	
NASVIPEGQ	Myosin heavy chain, fast skeletal muscle	913,45	
DEAGPSIVH	Actin, alpha skeletal muscle	923,43	
FIGMESAGI	Actin, alpha skeletal muscle	923,44	
FLGMESAGI	Actin-2	923,44	
VNDAFGTAH	Phosphoglycerate kinase	930,42	
LEEAGGATSV	Myosin-7	932,44	
GVDNPGHPF	Creatine kinase M-type	938,42	
IIEGDLER	Tropomyosin alpha-1 chain	943,50	
LGAHAIHAGL	REVERSED Chlorophyll a/b light-harvesting protein PcbC	958,53	
NIIHGSDTL	Nucleoside diphosphate kinase B (Fragments)	968,49	
DVILPVPAPF	Alpha-enolase	969,55	
SELEELK	Tropomyosin alpha-1 chain	975,47	
AGFAGDDAPR	Actin, alpha skeletal muscle	975,44	
VLDAGDGVTH	Actin, alpha skeletal muscle	982,47	
TQLEELK	Myosin-13	987,52	
DVPGPVGIPF	Titin	996,53	
EELEAER	Myosin heavy chain, cardiac muscle isoform (Fragment)	1003,44	
APEEHPTLL	Actin, alpha skeletal muscle	1005,51	
SYELPDGQV	Actin, alpha skeletal muscle	1006,46	
ASISAFGSNY	Lipase	1015,46	
NLTEEMASQ	Myosin heavy chain, fast skeletal muscle	1021,44	
SEELDHAN	Tropomyosin alpha-1 chain	1026,46	
MILPVGAANF	Alpha-enolase	1031,55	

YELPDGQVI	Actin, alpha skeletal muscle	1032,51	
AGLLGTLEEM	Myosin-4	1032,52	
SLEAQAEKY	Tropomyosin alpha-1 chain	1037,50	
NASVIPEGQF	Myosin heavy chain, fast skeletal muscle	1060,52	
TKYETDAIQ	Myosin heavy chain, fast skeletal muscle	1067,51	
GTEDELDKY	Tropomyosin alpha-1 chain	1068,46	
DLEESTLQH	Myosin heavy chain, fast skeletal muscle	1070,49	
ADIAESQVNK	Myosin-4	1073,53	
LDKENALDR	Tropomyosin alpha-1 chain	1073,53	
AVIDQDKSGF	Parvalbumin alpha	1078,53	
DEQSLGAQLQ	Myosin heavy chain, fast skeletal muscle	1087,51	
FDKIEDMAM	Myosin heavy chain, fast skeletal muscle	1098,47	
VAPEEHPTLL	Actin, alpha skeletal muscle	1104,58	
QIEDFKEAF	Myosin light chain 3, skeletal muscle isoform	1108,51	Gln->pyro-Glu@N-term
KEYPEMGK	Sarcoplasmic/endoplasmic reticulum calcium ATPase 1	1109,50	
SYELPDGQVI	Actin, alpha skeletal muscle	1119,54	
NFDKVLAEW	Myosin heavy chain, fast skeletal muscle	1120,55	
SGFIEEDELK	Parvalbumin alpha	1165,55	
SGGTTMYPGIA	Actin, alpha skeletal muscle	1053,48	

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931 **Table 3**

932 Comparison of some identified peptides with previously identified bioactive peptides basing
 933 on Biopep data bases.

Hydrolysate		Peptide sequence		Previously identified bioactive peptides	
			Sequence	Activity	Reference
SPH-A26	P1	LDDFKL	GAQCTAGPCCWPCEGTICRR ARGDDLDDYCNGISADCPRN PYY	Antithrombotic	Yeh, Peng, Yih & Huang, 1995
	P2	ALDILDAA	KKALRRQEAVDAA	Kinases inhibitor	Ishida et al. 1998
	P3	IDFGFDL	MFDL	ACE inhibitor	Murray & FitzGerald, 2007
	P4	LNPTNASH	LNPPHQIYP LNP LNPA	ACE inhibitor ACE inhibitor ACE inhibitor	Kohmura et al. 1989 Miyoshi, Ishikawa, Kaneko, Fukui & Tanaka, 1991 Yano, Suzuki & Funatsu, 1996
	P5	AGRDLTDY	TDY	Antioxidant	Liu et al. 2015
	P6	LIENDEAL	KKALRRQEALDAL TPEVDDEALEK	Kinase inhibitor DPP IV inhibitor	Ishida et al. 1998 Silveira, Martínez-Maqueda, Recio & Hernández-Ledesma, 2013
	P7	TALEEAEGT	KVREGT	ACE inhibitor	Lee, Cheng, Enomoto & Nakano, 2006
	P8	LEEEVGAAK	LEEELEELEGCE	Antioxidative	Qian, Jung & Kim, 2008
	P9	NVPVYEGY	LYEGY LVVDGEGY	Antioxidative ACE inhibitor	Liu et al. 2015 Esteve, Marina & Garcia, 2015
	P10	ILAADESTGS	ILAP	DPP IV inhibitor	Harnedy, O'Keefe & FitzGerald, 2015
	P11	IEFNVLVQ	GKKVLVQ	ACE inhibitor	Mito et al. 1996
	P12	KDIDDLELT	LRENNKLMLELK	Antioxidant, ACE inhibitor and DPP IV inhibitor	Mojica, Chen & de Majia, 2015
	P13	VFKDLFDP	VFK	ACE inhibitor	Pihlanto-Leppala, Koskinen, Piilola, Tupasela & Korhonen, 2000
	P14	ISEELDHAL	ISELGW	Antioxidative	Tsopmo, Romanowski, Banda, Lavoie & Jenssen, 2011
	P15	GTNDETERQ	EKERERQ	ACE inhibitor	Katayama et al. 2008
	P16	VIPELDGKLT	EEEKNRLTKKTKLT	Antioxidant	Srinivas & Prakash, 2008
	P17	TIHGLGPRQS	TIPLPV	Antioxidative	Jiménez-Escrig, Alaiz, Vioque & Rupérez, 2010
	P18	ILPDGDHDLK	ILP	ACE inhibitor	Kohmura et al. 1989
SPH-An6	P19	EVIEIQ	LREIQILLRF	Kinase inhibitor	Ishida et al. 1998
	P20	LEEAGGATAA	LEEELEELEGCE	Antioxidative	Qian, Jung & Kim, 2008
	P21	ITALAPSTM	SALAM	Antioxidative	Hernandez-Ledesma, Amigo, Recio & Bartolome, 2007
			ALAV	DPP IV inhibitor	Harnedy, O'Keefe & FitzGerald, 2015
	P22	VGPLGRSGAP	MDGAP; VGPLSPT	Antioxidant	Esteve, Marina & García, 2015
	P23	SELEELK	LRENNKLMLELK	Antioxidant,	Mojica, Chen & de Mejia, 2015
ACE inhibitor and DPP IV inhibitor					

P25	SGFIEEDELK			
P26	VLDAGDGVTH	VLDTDYK	ACE inhibitor	Pihlanto-Leppala, Koskinen, Piiola, Tupasela & Korhonen, 2000
		VLDTGLAGA	Antioxidant	Esteve, Marina & García, 2015
P27	EEELEAER	EEE	Stimulating vasoactive	Ringseis et al. 2005
		EEEKNRLTKKTKLT	Antioxidant	Srinivas & Prakash, 2008
P28	APEEHPTLL	APER	ACE inhibitor	Salampessy, Reddy, Kailasapathy & Phillips, 2015
P29	SEELDHALN	EELDNALN	Antioxidant	Saiga, Tanabe & Nishimura, 2003
P30	MILPVGAANF	MILMR	Antioxidant	Chi et al. 2014
		MILLFR	ACE inhibitor	Toopcham, Roytrakul & Yongsawatdigul, 2015
P31	SLEAQAEKY	VIEKYP	ACE inhibitor	Murray & FitzGerald, 2007
P32	NASVIPEGQF	YIEAVNKVSPRAGQF	ACE inhibitor	Zambrowicz et al. 2015
P33	GTEDELDKY	SFLLRNPNDKYEPF	Antithrombotic	Connolly et al. 1994
P34	VAPEEHPTLL	VAP	ACE inhibitor	Maruyama, Mitachi, Tanaka, Tomizuka & Suzuki, 1987
P35	QIEDFKEAF	DWLKAFYDKVAEKLKEAF	Lipids binding	Garber et al. 2006

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951 **Table 4**

952 List of synthesized peptides, molecular weight and purity.

	Synthesized peptide sequences	MW (g mol ⁻¹)	Purity (%)
	P1 LDDFKL	749.86	99
	P5 AGRDLTDY	909.94	98.1
	P6 LIENDEAL	915.39	99.3
	P8 LEEEVGA AK	945.03	94.6
	P9 NVPVYEGY	940.01	98.7
	P12 KDIDDLELT	1061.15	99.1
	P14 ISEELDHAL	1026.1	98.4
	P15 GTNDETERQ	1049.01	96.5
	P19 EVIEIQ	729.82	98.9
	P21 ITALAPSTM	904.09	97.9
	P23 SELEEELK	976.04	97.7
	P29 SEELDHALN	1027.05	87.6
	P31 SLEAQAEKY	1038.11	99.4
	P33 GTEDEL DKY	1069.08	95.5
	P35 QIEDFKEAF	1126.22	86

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972 **Table 5**973 IC₅₀ values of ACE-inhibitory, DPPH free radical scavenging and β-carotene inhibition
974 bleaching activities of synthesized peptides identified in SPH-A26 and SPH-An6.

975

Peptide			ACE-inhibitory activity IC ₅₀ (mM)	Scavenging effect on DPPH free radical IC ₅₀ (mM)	β-carotene bleaching activity IC ₅₀ (mM)
	P1	LDDFKL	nd	1.98 ± 0.02 ^b	0.63 ± 0.06 ^c
	P5	AGRDLTDY	nd	1.54 ± 0.01 ^d	0.48 ± 0.01 ^d
	P6	LIENDEAL	nd	3.38 ± 0.11 ^a	nd
	P8	LEEEVGAAK	nd	1.64 ± 0.03 ^c	1.03 ± 0.05 ^a
	P9	NVPVYEGY	0.21 ± 0.003 ^c	1.41 ± 0.03 ^{d,e}	1.11 ± 0.02 ^a
	P12	KDIDDLELT	nd	nd	0.34 ± 0.01 ^e
	P14	ISEELDHAL	nd	nd	0.22 ± 0.01 ^f
	P19	EVIEIQ	nd	nd	0.31 ± 0.05 ^e
	P21	ITALAPSTM	0.229 ± 0.01 ^c	nd	0.64 ± 0.001 ^c
	P23	SELEEELK	nd	1.67 ± 0.02 ^c	0.99 ± 0.05 ^a
	P31	SLEAQAEKY	0.406 ± 0.02 ^b	nd	nd
	P33	GTEDELDKY	nd	1.32 ± 0.01 ^e	0.82 ± 0.05 ^b
	P35	QIEDFKEAF	0.735 ± 0.02 ^a	nd	0.97 ± 0.01 ^a

976

977 nd: not determined

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994 **Figure captions**

995

996 **Fig. 1.** ACE-inhibitory activity of sardinelle muscle proteins fermented by *B. subtilis* A26
997 (SPH-A26) and *B. amyloliquefaciens* An6 (SPH-An6) at different concentrations. Values are
998 means of three independent experiments.

999

1000 **Fig. 2.** Antioxidant activities of sardinelle protein hydrolysates (SPH-A26 and SPH-An6) at
1001 various concentrations. Scavenging effect on DPPH free radical (a), reducing power (b), β -
1002 carotene bleaching activity (c), chelating effect (d), oxygen radical absorbance capacity
1003 (ORAC) (e). Values are means \pm SD (n = 3).

1004

1005 **Fig. 3.** Distribution of peptides identified in SPH-A26 (a) and SPH-An6 (b) by nESI-LC-
1006 MS/MS according to their protein of origin.

1007

1008 **Fig. 4.** ACE-inhibitory activity of synthesized peptides in SPH-A26 and SPH-An6 at a
1009 concentration equal to 0.25 mM. The values represent means of three independent
1010 experiments \pm SD.

1011

1012 **Fig. 5.** Antioxidant activities of synthesized peptides in SPH-A26 and SPH-An6: Scavenging
1013 effect on DPPH free radical at a concentration equal to 1 mM (a), reducing power at a
1014 concentration equal to 0.3 mM (b), β -carotene bleaching activity at a concentration equal to 1
1015 mM (c), oxygen radical absorbance capacity (ORAC) at a concentration equal to 0.25 mM
1016 (d). The values represent means of three independent experiments \pm SD.

1017

1018

1019

1020

1021

1022

1023

1024


1025

1026

1027

1028 **Fig. 1.**

1029



1030

1031

1032

1033

1034

1035

1036

1037

1038

1039

1040

1041


1042

1043

1044


1045 **Fig. 2.**

1046 **a**




1056


1057 **b**



1071 c



1082 d



1098

e

1099

1100

1101

1102

1103

1104

1105

1106

1107

1108

1109

1110

1111

1112

1113

1114

1115

1116

1117

1118

1119


1120

1121

1122

1123

1124



1125 **Fig. 3.**

1126

a

1127

1128

1129

1130

1131

1132

1133


1134

1135

1136

1137

1138



1139

b

1140

1141

1142

1143

1144

1145

1146


1147

1148

1149


1150

1151



1152 **Fig. 4.**

1153



1154

1155

1156

1157

1158

1159

1160

1161

1162

1163

1164

1165

1166

1167

1168

1169


1170

1171 **Fig. 5.**

1172

a

1173




1174

1175

1176

b



1177

1178


1179

1180

1181

1182

c




1183

1184

1185

1186

d



1187

1188

1189

1190

1191

1192